Narrative reviewindependent cross-checkabstract checked I-UPF-122 standard review

Industry-linked critique of the EU titanium dioxide decision

Safety of titanium dioxide (E171) as a food additive for humans.

Overview

Warheit DB. Front Toxicol 2024 · PMID 39100893 · DOI 10.3389/ftox.2024.1333746

A former employee of a titanium dioxide maker argues that EFSA was wrong and says other countries' agencies disagreed.

Does the study support the specific claim? No · Methodological quality: very low

Original publication

Plain-language summary

Study explained simply
What did the researchers want to find out?

To argue against EFSA's E171 conclusion.

How was the study done?

Opinion article.

How many people, animals or samples were studied?

Not applicable.

What was actually found?

Claims EFSA misjudged the genotoxicity data.

How large was the observed effect?

Not applicable.

What do the results mean in everyday life?

Regulators disagree; the EU still banned it.

What are the study's limitations?

Strong conflict of interest.

What does it say about Elawady's specific claim?

Limits but does not refute C-UPF-09.

Do the results apply to Germany and Europe?

EU ban stands.

What can explicitly not be concluded from this study?

Cannot show E171 is safe.

Scientific in-depth review

1. Full reference

Authors
Warheit DB
Journal
Front Toxicol
Year
2024
Identifier
PMID 39100893 DOI 10.3389/ftox.2024.1333746 · PMC11295244
Verification
verified – PubMed efetch 2026-10-26; Crossref works API 2026-10-26
Retracted
no
Corrections
none
Extent checked
abstract only
Conflicts of interest and funding

COI statement in record: author employed by Warheit Scientific LLC; former employee of DuPont de Nemours/Chemours Inc, a titanium dioxide producer.

2. Research question

Was EFSA's 2021 conclusion on E171 justified?

3. Study design and population

Study design
Narrative review – Perspective (narrative review) by a former employee of a titanium dioxide producer
Population

Not applicable

Country

Not applicable

Period

2024

Sample size

Not applicable

Inclusion and exclusion criteria

Not applicable

4. Methods and endpoints

Exposure / intervention

TiO2 (E171)

Comparator

Not applicable

Endpoints

Not applicable

Statistical methods

Not applicable

5. Actual results

Results

Argues EFSA made a 'manifest error': key genotoxicity studies used dispersed/sonicated nanoparticles not representative of E171; low oral absorption in rats and humans; states that UK, Canadian, Australian and New Zealand agencies generally disagreed with EFSA's opinion; cites an expert group that found no support for a direct DNA-damaging mechanism.

Absolute risks

Not applicable

Authors' conclusion

EFSA made a manifest error on the safety of E171 as a food additive (author's view).

6. Strengths

  • Documents disagreement among regulators

7. Weaknesses

  • Single author with industry ties (former DuPont/Chemours employee)
  • Opinion piece; agency positions not verified here from primary sources

8. Risk of bias

Orienting tool
none applicable
Type of assessment
simplified assessment (abstract only)
Full formal assessment
no
Overall risk of bias
high
Rationale

Strong potential conflict of interest.

9. Assessment of the statistical interpretation

Not applicable.

10. Relevance to the specific claim

Shows that EFSA's conclusion is contested by some regulators and industry-linked scientists; does not change the fact that EFSA concluded E171 can no longer be considered safe and the EU withdrew it.

11. Independent contrary findings

EFSA 2021 (A-UPF-21).

12. Transferability to Germany and Europe

E171 banned in EU food since 2022; other jurisdictions differ.

13. Overall methodological judgement

Weak, conflicted source; useful only to document the controversy.

Multidimensional assessment
Multidimensional assessment
Authenticity of the sourceverified
Methodological qualityvery low
Risk of biashigh
Precision of resultsnot applicable
Directnessdirect
Reproducibilityunknown
Consistency with the overall evidencemixed
Regional transferabilitymoderate
Adequacy of the interpretation (by the archive)not applicable

14. Open questions

Verified statements of FSANZ, Health Canada, UK FSA (not fetched).

15. Linked fact checks